Women’s health’ offers a distinct medical term for half the global population, but is it causing more harm than good? Some ...

Better headline sales growth than Johnson & Johnson the previous week should have been well-received by Roche’s investors.

In the first instalment of Scrip’s two-part video interview, Lilly’s Jacob Van Naarden discusses its key presentations at ...

European Medicines Agency officials say streamlining its committee structure will require new ways of organizing scientific ...

Speaking at the MedTech Conference in Boston, CDRH director Michelle Tarver said the center authorized 151 novel devices in ...

Efficacy among previously treated HR+/HER2- breast cancer patients looked in line with Merck/Kelun’s sac-TMT, but an analyst ...

NAD found “fatal flaws” in three studies Oral Essentials submitted in second review of “30 minutes to whiter teeth” claim it ...

Following a refuse-to-file letter and a complete response letter, Biohaven’s drug will be reviewed by the FDA for approval in ...

Former FDA officials at a NAMSA-hosted panel urged medical device manufacturers to maintain inspection readiness under the ...

NRx Pharmaceuticals has received a discipline review letter from the US Food and Drug Administration requesting "minor” ...

A white paper on “Digitally Derived Measures” stresses that the process of incorporating them into clinical trials must start ...

The biotech plans to seek full approval in the fourth quarter based on positive data from the Phase III ORIGIN 3 trial.